rta 744

Small moleculeexperimental

Clinical trial activity

7 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2005 (NCT00526812)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1
Mol. weight
633.65 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • berubicin
  • berubicin
  • berubicin hcl
  • berubicin hcl
  • berubicin hydrochloride
  • berubicin hydrochloride
  • berubicin hydrochloride
  • rta 744
  • rta 744
  • rta 744
  • rta-744
  • rta-744
  • wp744
  • wp744

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05082493Phase 1Oct 31, 2021Worldwide Clinical Trials, WPD Pharmaceuticals Sp. z o.o.
NCT04915404Phase 1/Phase 2 (Phase 2)Jul 15, 2021Government of Poland, Worldwide Clinical Trials, WPD Pharmaceuticals Sp. z o.o.
NCT04762069Phase 2May 18, 2021CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
NCT00538343Phase 2Oct 1, 2007Reata Pharmaceuticals, Inc.
NCT00527410Phase 1Oct 1, 2006Reata Pharmaceuticals, Inc.
NCT00512460Phase 1Sep 1, 2006Reata Pharmaceuticals, Inc., University of Texas at Houston
NCT00526812Phase 1Nov 1, 2005Reata Pharmaceuticals, Inc.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Reata Pharmaceuticals, Inc.For profit4322005
Worldwide Clinical TrialsFor profit3022021
WPD Pharmaceuticals Sp. z o.o.For profit2222021
CNS Pharmaceuticals, Inc.For profit1112021
Government of PolandGovernment1012021
University of Texas at HoustonAcademic/Hospital1112006
6 organizations
Page 1 / 1